Dr. Reddy’s Launches Generic Semaglutide Injection in Canada
Hyderabad, May 16 (TNT): Hyderabad-based global Pharmaceutical major Dr. Reddy’s Laboratories on Saturday announced the launch of its generic Semaglutide Injection in Canada.
Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market following the Notice of Compliance (NOC) granted by Health Canada on April 28, 2026.
Canada has become the first G7 nation to grant market authorisation for generic Semaglutide Injection, marking a significant milestone in the global expansion of GLP-1 therapies.
According to the company, the launch reflects Dr. Reddy’s preparedness to ensure rapid patient access following regulatory approval.
In Canada, Dr. Reddy’s Semaglutide Injection is indicated as a once-weekly treatment for adults with Type 2 Diabetes Mellitus to improve glycaemic control alongside diet and exercise.
The medication is supplied as a sterile solution for subcutaneous injection in pre-filled pens and is available in 2 mg/pen and 4 mg/pen strengths. Each pen delivers semaglutide at a concentration of 1.34 mg/ml.
The 2 mg pen is designed to administer 0.25 mg or 0.5 mg doses, while the 4 mg pen delivers 1 mg per injection.
Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We are pleased to launch our generic Semaglutide Injection in Canada within days of receiving Health Canada approval. This milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development.”
“With our well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality and affordable GLP-1 therapies closer to patients,” he added.
The Canada launch follows the company’s recent introduction of the drug in India under the brand name Obeda®.
“As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” Erez Israeli said.
Semaglutide Injection is intended for adult patients with Type 2 diabetes to improve glycaemic control in combination with diet and exercise, particularly where metformin is unsuitable due to contraindications or intolerance.
The company clarified that Semaglutide has not been studied in combination with short-acting prandial insulin and should not be considered a substitute for insulin.
It is also not indicated for patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.
TNT TS
